20 articles
Fisetin encapsulated in liposomes significantly reduces IL-6 and IL-8 secretion in senescent lung cells, revealing potent senomorphic but not senolytic activity.
A new mouse study shows fisetin senolytic treatment reverses age-related endothelial dysfunction by eliminating senescent cells and reducing the SASP factor CXCL12.
A Phase 2 pilot trial investigates whether the natural senolytic compound fisetin can reduce dysfunction and complications in COVID-19 patients.
Intermittent fisetin dosing in old mice reduced frailty and boosted grip strength, matching results from genetic and synthetic senolytic approaches.
A 2026 review evaluates how two common dietary flavonoids target senescent cells, potentially slowing aging and age-related disease.
A flavonoid found in strawberries activates a key nuclear receptor to slash cholesterol and reverse arterial plaque in mice.
A comprehensive review reveals fisetin's broad therapeutic potential spanning senescence, neurodegeneration, and cancer — with key bioavailability hurdles to overcome.
A multiomics and network pharmacology study reveals fisetin reduces alveolar bone loss and protects periodontal fibroblasts from oxidative damage.
New research shows removing senescent cells with fisetin dramatically reduces dangerous heart rhythm disorders in aging rabbits.
Combining the flavonoid fisetin with SGLT2 inhibitor dapagliflozin outperformed either drug alone in restoring hormones, reducing oxidative stress, and normalizing reproductive cycles in PCOS rats.
Two natural compounds suppress cellular senescence in osteoarthritic cartilage progenitor cells, reducing inflammatory SASP markers via p53 pathway.
Two natural polyphenols reverse amyloid-beta damage in human neurons by restoring mitochondrial health, autophagy, and synaptic function.
A new class of retro-inverso peptides selectively destroys senescent brain cells via the FOXO4-p53 axis, restoring cognition in aged animal models.
A medicinal-chemistry optimized flavonol called F-4N shows 50× greater senolytic potency than quercetin and resolves lung fibrosis in animal models.
Clinical trial tests whether senolytic compounds can reduce cellular aging burden and improve bone health markers in older adults.
Clinical trial tests whether dasatinib plus quercetin can reduce liver scarring in fatty liver disease patients.
Four anti-aging compounds — quercetin, fisetin, dasatinib, and sirolimus — all shifted gut microbiome composition toward healthier aging profiles.
Comprehensive review reveals how drugs that eliminate or modify senescent cells could revolutionize anti-aging medicine.
New research reveals how drugs that eliminate senescent cells could complement existing Alzheimer's treatments by reducing brain inflammation.
Researchers identify NUF2 as a key driver of prostate cancer and discover fisetin, a natural compound, as a promising inhibitor of this oncogene.
